according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Timolol / Dorzolamide Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Piercetown

A86 HD21 Dunboyne, Ireland

Telephone : 908-740-4000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 1, Cardio-vascular system, Central nervous system, Gastro-intestinal tract, Lungs

H372: Causes damage to organs through prolonged or repeated exposure.

intestinal tract, Eurig

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word : Danger

Hazard statements : H372 Causes damage to organs (Cardio-vascular sys-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

tem, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated expo-

sure.

Precautionary statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this prod-

uct.

Response:

P314 Get medical advice/ attention if you feel unwell.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Dorzolamide	130693-82-2	Acute Tox. 4; H302 STOT RE 2; H373 (Central nervous system, Gastrointes- tinal tract, Bone, Blood, Bladder)	>= 1 - < 10
(S)-3-[3-(tert-butylamino)-2- hydroxypropoxy]-4-morpholino- 1,2,5-thiadiazole monomaleate	26921-17-5 248-111-5	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Lungs, Cardio- vascular system)	>= 0.1 - < 1

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Causes damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

: None known.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Nitrogen oxides (NOx) Sulphur oxides

Hydrogen chloride

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth- :

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoi

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

		of exposure)			
Dorzolamide	130693-82-	TWA	10 μg/m3 (OEB 3)	Internal	
	2				
	Further information: Eye				
		Wipe limit	100 μg/100 cm ²	Internal	
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazolemonomaleate	26921-17-5	TWA	10 μg/m3 (OEB 3)	Internal	
	Further information: Eye, Skin				
		Wipe limit	100 μg/100 cm ²	Internal	

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 3.18
 28.09.2024
 28809-00026
 Date of first issue: 06.11.2014

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : colourless

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : 5.6

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Relative density : 1.02

Density : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 28809-00026 Date of first issue: 06.11.2014 3.18

Components:

Dorzolamide:

Acute oral toxicity : LD50 (Rat): 1,927 mg/kg

LD50 (Mouse): 1,320 mg/kg

Acute inhalation toxicity Remarks: No data available

Remarks: No data available Acute dermal toxicity

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Acute oral toxicity LD50 (Rat): 1,000 mg/kg

LD50 (Mouse): 1,140 mg/kg

Acute toxicity (other routes of:

LD50 (Mouse): 300 mg/kg

administration) Application Route: Intraperitoneal

LD50 (Mouse): 800 mg/kg

Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Rabbit Method **Draize Test** Result No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Dorzolamide:

Species Monkey

Result Mild eye irritation

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Rabbit

Result Mild eye irritation

Species Dog

Result No eye irritation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Dorzolamide:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

Dorzolamide:

Genotoxicity in vitro : Test Type: Chromosomal aberration

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Cytogenetic assay

Species: Mouse Result: negative

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Method: OECD Test Guideline 474

Result: negative

Carcinogenicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 3.18
 28.09.2024
 28809-00026
 Date of first issue: 06.11.2014

Components:

Dorzolamide:

Species : Rat, male
Application Route : Oral
Exposure time : 2 Years

: 20 mg/kg body weight

Result : negative

Remarks : The mechanism or mode of action may not be relevant in hu-

mans

Species : Mouse Application Route : Oral

Exposure time : 21 month(s)
Result : negative

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 300 mg/kg body weight

Result : negative Target Organs : Adrenal gland

Remarks : The significance of these findings for humans is not certain.

Species : Mouse, female

Application Route : Oral Exposure time : 18 Months

LOAEL : 500 mg/kg body weight

Result : negative

Target Organs : Lungs, Mammary gland, Uterus (including cervix)

Remarks : The significance of these findings for humans is not certain.

Carcinogenicity - Assess-

Weight of evidence does not support classification as a car-

ment

cinogen

Reproductive toxicity

Not classified based on available information.

Components:

Dorzolamide:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female

Application Route: Oral

Fertility: NOAEL: 7.5 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: NOAEL: 1 mg/kg body weight

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight Early Embryonic Development: NOAEL F1: 150 mg/kg body

weight

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: LOAEL F1: 50 mg/kg body weight Result: Some evidence of adverse effects on development,

based on animal experiments.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.

Product:

Target Organs : Cardio-vascular system, Central nervous system, Gastrointes-

tinal tract, Lungs

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Components:

Dorzolamide:

Target Organs : Central nervous system, Gastrointestinal tract, Bone, Blood,

Bladder

Assessment : May cause damage to organs through prolonged or repeated

exposure.

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Target Organs : Lungs, Cardio-vascular system

Assessment : Causes damage to organs through prolonged or repeated

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 3.18
 28.09.2024
 28809-00026
 Date of first issue: 06.11.2014

exposure.

Repeated dose toxicity

Components:

Dorzolamide:

Species : Rat

NOAEL : 0.05 mg/kg

Application Route : Oral

Target Organs : Bladder, Kidney

Species : Dog

NOAEL : 0.05 mg/kg
LOAEL : 2 mg/kg
Application Route : Oral
Exposure time : 1 yr

Target Organs : Gastrointestinal tract, Bone, Blood

Species : Monkey NOAEL : 0.05 mg/kg

Exposure time : 1 yr

Target Organs : Gastrointestinal tract, Bone, Blood

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species : Rat
NOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 67 Weeks

Species : Dog
NOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 54 Weeks
Target Organs : Kidney

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

Experience with human exposure

Product:

Eye contact : Symptoms: The most common side effects are:, bitter taste,

burning or stinging of the eye, Blurred vision, Abdominal pain, Dizziness, digestive disorder, eye pain, Headache, hyperten-

sion, Nausea, upper respiratory tract infection

Components:

Dorzolamide:

Eye contact : Symptoms: burning or stinging of the eye, Blurred vision, tear-

ing, asthenia, bitter taste, Nausea, dry mouth, Headache

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Eye contact : Symptoms: burning or stinging of the eye, dryness of the

eyes, Headache, Nausea, Dizziness, dry mouth, changes in

libido, hair loss, Allergic reactions

Ingestion : Symptoms: Headache, Fatigue, Respiratory disorders, Gas-

trointestinal discomfort, Allergic reactions, Rash, hair loss,

altered mental status, Dizziness, changes in libido

SECTION 12: Ecological information

12.1 Toxicity

Components:

Dorzolamide:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 699 mg/l

Exposure time: 48 h

Toxicity to microorganisms : EC50 (Natural microorganism): > 800 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 411 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 161 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to microorganisms : EC50 : > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

EC50 (Photobacterium phosphoreum): > 1,800 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

12.2 Persistence and degradability

Components:

Dorzolamide:

Biodegradability : Result: not rapidly degradable

Biodegradation: 5 % Exposure time: 28 d

Method: OECD Test Guideline 314

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 0 % Exposure time: 30 d

Stability in water : Hydrolysis: 0 %(61 d)

Method: FDA 3.09

12.3 Bioaccumulative potential

Components:

Dorzolamide:

Partition coefficient: n-

octanol/water

: log Pow: 0.292

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Partition coefficient: n-

octanol/water

: log Pow: 1.48

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

IMDG : Not regulated as a dangerous goodIATA (Cargo) : Not regulated as a dangerous goodIATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not. Not applicable

Not applicable

Not applicable

Not applicable

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H361d : Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H373 : May cause damage to organs through prolonged or repeated

exposure.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Timolol / Dorzolamide Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.18 28.09.2024 28809-00026 Date of first issue: 06.11.2014

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

STOT RE 1 H372 Based on product data or assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN